Spliced-Leader RNA as a Dynamic Marker for Monitoring Viable Leishmania Parasites During and After Treatment

J Infect Dis. 2024 Jul 25;230(1):183-187. doi: 10.1093/infdis/jiae219.

Abstract

Accurate detection of viable Leishmania parasites is critical for evaluating visceral leishmaniasis (VL) treatment response at an early timepoint. We compared the decay of kinetoplast DNA (kDNA) and spliced-leader RNA (SL-RNA) in vitro, in vivo, and in a VL patient cohort. An optimized combination of blood preservation and nucleic acid extraction improved efficiency for both targets. SL-RNA degraded more rapidly during treatment than kDNA, and correlated better with microscopic examination. SL-RNA quantitative polymerase chain reaction emerges as a superior method for dynamic monitoring of viable Leishmania parasites. It enables individualized treatment monitoring for improved prognoses and has potential as an early surrogate endpoint in clinical trials.

Keywords: PCR; diagnostics; leishmaniasis; surrogate marker; treatment response.

MeSH terms

  • Animals
  • Antiprotozoal Agents / therapeutic use
  • Biomarkers
  • DNA, Kinetoplast* / genetics
  • Humans
  • Leishmania / genetics
  • Leishmaniasis, Visceral* / diagnosis
  • Leishmaniasis, Visceral* / drug therapy
  • Leishmaniasis, Visceral* / parasitology
  • RNA, Protozoan / analysis
  • RNA, Protozoan / genetics
  • RNA, Spliced Leader* / genetics
  • RNA, Spliced Leader* / metabolism

Substances

  • DNA, Kinetoplast
  • RNA, Spliced Leader
  • RNA, Protozoan
  • Antiprotozoal Agents
  • Biomarkers